Oryzon Genomics SA, of Barcelona, Spain, gained approval of its clinical trial application from the Spanish Drug Agency to initiate a phase I study with ORY-2001 for the treatment of Alzheimer’s disease. ORY-2001 is described as a highly selective dual LSD1-MAOB inhibitor. The trial will be conducted at a university hospital in Barcelona to evaluate the safety, tolerability and pharmacokinetics of ORY-2001 in healthy subjects as well as the elderly population. ORY-2001 also is in preclinical development to assess the potential effectiveness in other neurodegenerative diseases.